177Lu-PSMA-617 showed promising response rates and delayed disease progression in patients with oligometastatic HSPC in this trial. In addition, most treatment-related adverse events were low grade.
[Articles] [177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study
The Lancet Oncology | | Bastiaan M Privé, Walter Noordzij, Constantijn H J Muselaers, Igle J de Jong, Inge M van Oort, Marcel J R Janssen, Maartje C Van Rijk, Willemijn A van Gemert, Bart Timmermans, Michel de Groot, Niven Mehra, Winald R Gerritsen, Marianne A Jonker, Emmanouil Alevroudis, Suzanne van der Gaag, Josephina C C Koppes, J P Michiel Sedelaar, André N Vis, Alexis Vrachimis, Daniela E Oprea-Lager, James Nagarajah
Topics: prostate-cancer, clinical-trials, research